The Study of ICP-248 in Patients With Mature B-cell Malignancies — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(22 sites)
China
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Peking University Third Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality Fujian Medical University Union Hospital, Fuzhou, Fujian The First Affiliated Hospital of Xiamen University, Xiamen, Fujian Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan The Central Hospital of Wuhan, Wuhan, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Jiangsu Province Hospital, Nanjing, Jiangsu The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Jiangxi Cancer Hospital, Nanchang, Jiangxi The Second Hospital of Dalian Medical University, Dalian, Liaoning Shenyang Hospital Of China Medical University, Shenyang, Liaoning Shandong cancer hospital, Jinan, Shandong Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality West China Hospital of Sichuan University, Chengdu, Sichuan Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Last updated September 2025